Abstract-Effects of intrarenal-arterial (i.r.a.) and intravenous (i.v.) infusions of PGE2, 12 and Fza on systemic blood pressure (BP), heart rate (HR), renal blood flow (RBF), urine volume (UV), renal function and plasma renin activity (PRA) of the renal venous blood (RVPRA) were investigated. A dose-dependent fall in BP was observed with PGE2 and 12 and was accompanied by a tachycardia (PGE2<12, i.r.a.<i.v.). PGEZ and 12 induced increases in RBF and UV in a roughly dose-dependent manner (PGE2> 12, i.r.a.>i.v.), however, antidiuresis was observed with the highest intravenously given dose of PGI2 (300 ng/kg/min) such being ascribed to a pronounced hypotension. Changes in electrolyte excretion induced by PGE2 and 12 were similar to the pattern of those in RBF or UV. Neither PGE2 or 12 produced any significant changes in the glomerular filtration rate (GFR). The diuretic effect of PGE2 and Fza correlated with osmolar clearance (Cos,71) (r-0.89, p<0.01 ; r=0.55, p<0.01) and free water clearance (Cixzo) (r=0.52, p<0.01 ; r=0.83, p<0.01), whereas that of PGI2, only with Cosm (r=0.74, p<0.01).
given dose of PGI2 (300 ng/kg/min) such being ascribed to a pronounced hypotension. Changes in electrolyte excretion induced by PGE2 and 12 were similar to the pattern of those in RBF or UV. Neither PGE2 or 12 produced any significant changes in the glomerular filtration rate (GFR).
The diuretic effect of PGE2 and Fza correlated with osmolar clearance (Cos,71) (r-0.89, p<0.01 ; r=0.55, p<0.01) and free water clearance (Cixzo) (r=0.52, p<0.01 ; r=0.83, p<0.01), whereas that of PGI2, only with Cosm (r=0.74, p<0.01).
PGF2a produced the weakest changes in the parameters described above. PGE2 and 12 (30 ng/kg/min, i.r.a.), but not PGF2a, produced a significant elevation of RVPRA without any significant change in BP. These findings suggest that PGE2 plays a primary role in the kidney, whereas PG12 is important in the regu lation of the systemic circulation, and that PGE2, 12 and F2a all have different modes of action in producing diuresis. Both PGE2 and 12 may participate in the control of renin secretion. PGI2 (prostacyclin; originally called PGX) was first labelled as an unstable substance that inhibited platelet aggregation (1) and has been shown to be synthesised in arteries, veins, heart, kidney and other tissues in different species including humans (1) (2) (3) (4) (5) . This PG has a different biological property from PGE2, since PGI2 survives the inactivation in the lung (6) , while PGE2 is largely inactivated during a single passage through the lung (7), and is thought to be a circulating hormone. PGI2 causes vasodilatation in rats (8) and dogs (9) , and has a vasodepressor action of approximately 4-8, 2 and 10 times greater than that of PGE2 in rats, rabbits (10) and dogs (11) , respectively. The renal action of PGI2 has, however, been less intensely investigated. There is no systematic comparison of the renal effects of PGE2, 12 and F2,1 in extensive dose ranges, and to my knowledge, there are no reports dealing with the renal effects of PGI2 in relation to its systemic and renal hemodynamic effects.
In the present study, an attempt was made to delineate the direct action of PG's on the excretory function of the kidney, differentiating it from hemodynamic intervention. For that purpose, the effects of PGE2, 12 and F2, on systemic and renal hemodynamics and renal function were studied by infusing these PG's in extensive dose ranges into the renal artery and cephalic vein.
MATERIALS AND METHODS
Mongrel dogs of either sex weighing 8-15 kg were used. The dogs were fasted overnight but allowed free access to water. On the day of the experiment, the dogs were anesthetized with morphine (1.5 mg/kg, s.c.), followed by 45 % urethane +4.5 % alpha-chloral ose (1.5 ml/ kg, i.v.). Supplemental doses of the latter two anesthetics were given when necessary. A cuffed endotracheal tube was inserted into the trachea and the dogs were artificially ventilated with room air. During the experiment, arterial P02i pCO2 and pH were measured at times to maintain P02 at 84-115 mmHg, pCO2 at 23-32 mmHg and pH at 7.26-7.48. The blood pressure was recorded from the right femoral artery with a pressure transducer (Nihon Kohden LPU-0.5). The heart rate was measured using a pulse rate tachometer (Nihon Kohden RT-5), which was triggered by the R wave of the standard limb lead II ECG. The right common carotid artery and right cephalic vein were cannulated for arterial blood sampling and for drug administration, respectively. Then a left retroperitoneal flank incision was made and the left renal artery and vein were carefully isolated from the sur rounding tissues. An electromagnetic flow-meter (Statham SP 2201) probe (2 or 3 mm diameter) was placed around the left renal artery and the renal blood flow (RBF) was measured. A 21-gauge needle was inserted into the renal artery proximal to the flow probe for infusions of drugs. In some experiments, a vinyl tube was inserted through the right jugular vein and advanced into the left renal vein to obtain samples for determination of plasma renin activity (PRA). The left ureter was also cannulated for urine collection and urine volume (UV) was recorded continuously with a spike counter (Dia Medical System
Co., DSE-322A) which integrates the signal from an electronic drop counter for 30 seconds.
After completion of the surgical procedure, a stomach tube was inserted through the oral cavity and water (30 ml/kg) was continuously given through this tube. An initial dose of inulin (15 mg/kg) was administered intravenously. Thereafter, a solution containing 5 g of inulin in 1L of 0.9 % saline was infused continuously into the cephalic vein at a rate of 4 ml/ min throughout the experiment. Approximately 90 minutes were allowed for equilibration prior to commencing the experiment. Drugs used were PGE2, PGI2 as the sodium salt, PGF2a (these PG's were kindly provided by Ono Pharmaceutial Co., Ltd., Osaka), indomethacin (Nippon Merck-Banyu Co., Ltd.) and propranolol (ICI Pharma). PG's were dissolved in 99.5 % ethanol (1 mg/ml) and The renal vascular resistance (RVR) was calculated from the formula:
Statistical analysis was performed using the Student's paired t-test. All significant differences shown in the present study are from the corresponding control.
RESULTS
Effects of PG's on systemic blood pressure (BP) and heart rate (HR): Infusions of PGE2 and 12 resulted in a dose-dependent fall in BP and an increase in HR. However, in 2 out of 6 cases of 300 ng/kg/min of PGI2 administered into the renal artery bradycardia, not tachycardia, was observed. Intravenous infusions of both PG's produced greater responses than did infusion into the renal artery, and PGI2 was more potent in producing hypotension and tachycardia than PGE2, except when the highest doses of PGI2 were infused into the renal artery, 300 ng/kg/min there was a smaller increment in HR. In contrast to the above two PG's, infusion of PGF2a produced only slight changes in BP and HR; a significant increase in HR was observed only with a dose of 300 ng/kg/min, i.v. (Fig. 1) .
Effects of PG's on renal blood flow (RBF) and urine volume (UV): Infusions of PGE2 and 12 resulted in increases in RBF and UV, except for the highest dose of intravenously given PGI2 (300 ng/kg/min), which produced an antidiuresis. The responses to PGE2 and I2 were dose-dependent, except those to the highest dose of the compounds infused into the renal artery (300 ng/kg/min) which showed a tendency to become weaker. Infusions into the renal artery produced greater responses than intravenous infusions except for the highest dose of PGI2 (300 ng/kg/min). Infusions into the renal artery of PGE2 produced greater responses of RBF than PGI2, whereas intravenous infusions of PGI2 produced greater responses of RBF than those of PGE2. With regard to the diuretic effects, PGEZ was more potent than PGI2. PGF2a caused an increase in UV and here there was no significant change in RBF (Fig. 2) . Effects of PG's on renal function: Infusions of PGE2 and 12 produced significant increases in UNaV, UKV and UC1V except for the highest dose of intravenously given PGI2
(300 ng/kg/min), which produced a significant decrease. There were no significant changes in GFR with any dose given. The increases in urinary ion excretion were observed in a roughly dose-dependent manner, and were similar to the pattern of UV changes. The changes in Cosm caused by PGE2 and I2 were also similar to the pattern of changes in UV, while changes in CHZo were variable. The changes in RVR and FF caused by PGE2 and 12
were in inverse proportion to the pattern of changes in RBF, particularly with PGI2.
Responses of UNaV, UKV, UC1V and Cosm to intrarenal-arterial infusion of PGEZ were greater than those of PGI2, whereas intravenous infusion of PGI2 was more potent than that of PGE2 (Tables 1, 2 ). PGF2,1 produced no significant changes in GFR, UKV, Cosm, CHZo and FF, but did induce slight and significant changes in UNaV, UC1V and RVR. The changes caused by PGF2a were much less when compared to those produced by PGE2 and 12 (Table 3) . Diuretic effects of PG's and clearance study: The relation between changes in UV and those in Cosm, and between changes in UV and those in CH Zo were investigated. In the case of PGE2, there were positive correlations between UV and C osn, (r-=0.89, p<0.01) and between UV and C11 20 (r=0.52, p<0.01) (Fig. 4) , while in the case of PGI2i there was a positive correlation between UV and Cosm (r=0.74, p<0.01) but no such correlation between UV and CH 2O (Fig. 5) . In the case of PGF2a, there were positive correlations between UV and Cosm (r=0.55, p<0.01), and between UV and CH Z0 (r=0.83, p<0.01) (Fig. 6 ). Effects of single intravenous injections of PG's: As most of the experiments conducted so far involved the single injection method, we gave single intravenous injections of PGE2 and 12 and found that with PGI2>PGE2 a significant hypotension occurred, while PGF2a produced a significant hypertension. The duration of the hypotensive action induced by PGE2 (3 /Lg/kg) was about 1-13 minutes and that by PGI2 (3 gig/kg) was about 6-25 minutes .
The duration of the hypertensive action induced by PGF2, (3 fig/kg ) was about 3-15 minutes. As for HR, all PG's tended to induce an increase, and only PGE2 produced a significant change. In 2 out of 5 cases of single intravenous injections of PGI2, bradycardia was observed. All PG's produced increases or biphasic changes in RBF (initial short decreases followed by long increases). The duration of RBF increase induced by PGI2 was sub stantially longer than those of PGE2 and Fla. PGE2 and I2 resulted in a antidiuresis while PGF2a produced a diuresis. PGI2 was more potent in producing antidiuresis than PGE2 (Table 4) . Effects of PG's on plasma renin activity (PRA) of the renal venous blood (RVPRA):
PGE2, 12 and F2a infused into the renal artery at a rate of 30 ng/kg/min produced no sig nificant change in BP. Of the three PG's, PGE2 and I2 elevated the RVPRA significantly, while with PGF2a, there was no significant change, although there was a tendency toward decrease. In addition, the changes in RVPRA induced by all three PG's were recovered almost to the control values 20 minutes after cessation of infusions of the PG's (Fig. 7) . 
DISCUSSION
In the present study, intravenous administration of 300 ng/kg/min of PGE2 produced a hypotension of the nearly equal magnitude to that produced by intravenous administration of 30 ng/kg/min of PGI2, and these findings are in agreement with the recent report of Fitzpatrick et al. (11) that the vasodepressor action of PGI2 was approximately 10 times greater than that of PGE2 in the dog. The fact that intravenous infusion of PGE2 and I2 produced a greater hypotension than infusion into the renal artery may easily be explained by assuming that PG's are inactivated mainly in the lung when they are infused intravenously, while PG's infused into the renal artery are inactivated both in the lung and kidney. A tachycardia was observed after administration of PGI2 together with a fall in BP. However, this may not be taken to represent a direct action of this compound on the cardiac pacemaker, for PGI2 was found to be without effects on the heart rate, when tested in the dog heart-lung preparation (Imai et al., unpublished). Armstrong et al. (10) reported that tachycardia induced by PGI2 was probably of reflex origin, for it was reduced in pithed animals, while the hypotensive effect persisted. In contrast, tachycardia observed after PGE2 was usually unaccompanied by hypotension, suggesting a direct effect of this compound on the cardiac pacemaker. A positive chronotropic effect of this compound was seen in the dog heart-lung preparation (Imai et al., unpublished). Unlike PGE2 or 12, continuous infusion of PGF2a was without effects on the BP, while a single intravenous administration of a rather high dose of PGF2a (3 ag/kg) produced a significant rise in BP. This may also be explained on the premise that the substance was inactivated more efficiently during passage through the lung when it is infused slowly rather than when it was injected during a short time. The effect of PGF2a on BP varies with the species of the animals used; it produces hypotension in the cat and rabbit (14, 15) , but hypertension in the rat and dog (16). Ducharme et al. (16) showed that the pressor action of PGF2a in the dog was associated with an increase in cardiac output and the peripheral resistance was virtually unchanged. Furthermore, they suggested that the increased cardiac output is attributable not to a direct effect of the agent on the myocardial contractility, but to the venous constriction and the consequent increase in the venous return. As for the mechanism of increase in the heart rate observed with the highest intravenous dose of PGF2a, a stimulation of the cardioregulatory center and the resultant increase in the sympathetic outflow (17) is conceivable, for Lavery et al. (18) demon strated that PGF2a could produce a tachycardia, when infused into the vertebral artery.
PGE2 and 12 caused increases in RBF in a roughly dose-dependent manner. Since the changes in the RBF produced by these two PG's were greater when they were infused into the renal artery than when administered intravenously, it is apparent that these two substances have a direct dilatatory action on the renal vasculature. In addition, the present study demonstrated that PGE2, more than PGI2, produced a greater increase in RBF when infused into the renal artery, therefore it may be that PGE2 possesses a stronger direct dilatatory effect on renal artery. The responses of UV and electrolyte excretion to intrarenal arterial infusion of PGE2 were also stronger than PGI2i indicating that PGE2 is more effective on the renal action than PGI2. Since a dose-dependent and significant decrease in FF was observed after PGI2, it seems that PGI2 produced an almost equivalent dilatation of afferent arterioles to that of efferent arterioles, or that changes in the latter was more prominent (19) . The magnitude of response of RBF to PGE2 (300 ng/kg/min, i.v.) was just in the middle between that to 0.3 ng/kg/min of PGE2 and that to 3 ng/kg/min infused into the renal artery, suggesting that about 90-99% of PGE2 is inactivated during a single passage from the cephalic vein to the renal artery, probably in the lung and this is essentialy in agreement with the results obtained by Ferreira and Vane (7) between UV and CH2o, while in the case of PGF2a that (r=0.83) between UV and C11 is greater than that (r=0.55) between UV and Cosm. The diuretic effect of PGI2 is related to the increase in Cosm only, this is in agreement with the findings of Gerber et al. (25) , who reported that PGI2 does not alter the CH ,o. Therefore, the present study suggests that PGE2, 12 and F2a all have different modes of action in producing dieresis. The antidiuretic effect of PGI2 observed with the highest intravenous dose used, i.e. 300 ng/kg/min was accompanied by a marked increase in RBF and a pronounced hypotension, but the change in GFR was not significant. Furthermore, intrarenal-arterial infusion of the same dose of PGI2 (300 ng/kg/min) produced diuresis. Therefore, it may be reasonable to assume that the antidiuresis was due to the pronounced hypotension induced by this compound.
It is known that the reductions in blood volume or in blood pressure are effective on stimulus for the release of vasopressin (ADH) (26, 27) . Clark and Silva (26) demonstrated that bilateral occlusion of the common carotid arteries induces the release of vasopressin.
Cousineau et al. (27) also showed that in hemorrhagic hypotension, vasopressin release was related more closely with the fall in diastolic pressure than with the actual decrease in blood volume. They concluded that a sudden variation in blood pressure is probably the most important stimulus for vasopressin secretion. Infusion of PGE1 generally induces diuresis, but Berl and Schrier (28) reported that the intravenous administration of PGE1 in a high dose (7 /tg/min) produced an antidiuresis, and suggested that this antidiuresis was due to the release of ADH provoked by the systemic hemodynamic effects of the high intravenous dose of PGE1, because the antidiuretic effect of intravenous PGE1 was not observed in hypophysectomized dogs. The antidiuresis induced by the high intravenous dose of PGI2
(300 ng/kg/min) may also be due to the release of ADH provoked by the pronounced hypo tension. The effects observed with single intravenous administrations of PG's may be taken to support the hypothesis, since antidiuresis with hypotension was observed with PGE2 and I2 whereas PGF2m caused diuresis with hypertension. In the present experiment, intravenous infusion of PGI2 (300 ng/kg/min) caused a significant decrease in Cosm, but CH Zowas essentially unchanged. This dissociation is in conformity with the findings described in the review of Hays and Levine (29) that there are two separate adenyl cyclases which can be activated by vasopressin, the one responsible for sodium transport and the other, for water flow and that PGE1 inhibited only the adenyl cyclase responsible for water flow.
Of the PG's shown to be produced in the kidney, PGE2, 12 and D2 were reported to produce increases in renin secretion whereas PGF2a was shown to produce decrease or no significant change (22, (30) (31) (32) (33) . In the present experiment, PGE2 and 12 (30 ng/kg/min, infused into the renal artery) caused significant increases in RVPRA without producing a significant change in BP, suggesting that PGE2 and 12 may participate in the control of renin secretion. Concerning the mechanisms by which PG's stimulate the renin release, it had been postulated that the electrolyte and water loss induced by PG's stimulates the renin-angiotensin system (34) . However, recently, the direct effects of PGE2 and 12 on renin secretion have been demonstrated (30, 32, 35) . Yun et al. (32) demonstrated that infusion of PGE2 into the renal artery of a "non-filtering" kidney caused an increase in renin secretion. Osborn et al. (35) reported that intrarenal-arterial infusions of acetylcholine, bradykinin, eledoisin and PGE2 increased RBF to a similar degree, and sodium excretion was similarly affected by these vasodilators, while renin secretion was increased only with PGE2.
In conclusion, the present study demonstrated that PGE2 induced greater responses of RBF, UV and electrolyte excretion than did PGI2, whereas PG12 was more potent in pro ducing hypotension and tachycardia than PGE2, suggesting that PGE2 plays a primary role in the kidney, whereas PGI2 is important in the regulation of the systemic circulation. In addition, PGE2, 12 and F2a all may probably have different modes of action in producing diuresis. The antidiuresis induced by the high intravenous dose of PG12 (300 ng/kg/min) may be due to the release of ADH provoked by the pronounced hypotension.
